Cuba is testing in Italy the efficacy of its vaccine against COVID-19 Soberana Plus, intended especially for convalescents of the coronavirus over 19 years old, the state pharmaceutical company BioCubaFarma reported on Tuesday.
SIGHT: Hospital corridors may have higher viral loads than COVID-19 patient rooms
“In Europe there is also interest (in Cuban vaccines). For instance, we have a scientific collaboration in Italy (…), where evaluations are being carried out in convalescent patients with a reinforcement dose of Soberana Plus ”, said at a press conference the president of BioCubaFarma, Eduardo Martínez.
And in those studies “It has been found that (the vaccine) has a strong level of neutralization, both of the Beta strain and the Delta strain”, he pointed.
SIGHT: EMA ends CureVac vaccine evaluation after trial cancellation
Soberana Plus, administered in a single dose to convalescents from COVID-19, also used as a third booster dose after the application of two of Soberana 02, another immunizer developed by the Finlay Institute of Vaccines of Havana.
Cuba has a third immunogen, Abdala, created by the Center for Genetic Engineering and Biotechnology (CIGB).
SIGHT: COVID-19 | Russia says its Sputnik Light vaccine is 70% effective against Delta variant
Vaccines Soberana 02, Soberana Plus and Abdala by BioCubaFarma They appear as interested in being evaluated by the WHO as of September 29, the latest update of PAHO of the prequalification process for immunizers before the WHO.
According to this document, all Cuban vaccines are based on a SARS-CoV-2 virus protein, chemically conjugated with meningococcus B, tetanus toxoid or aluminum.
These immunizers are more than 90% effective. to prevent disease with symptoms, according to its creators.
The green light from the WHO would boost the commercialization of Cuban vaccines, according to BioCubaFarma.
Martínez specified that, in addition to Iran, Vietnam, Nicaragua and Venezuela, countries that have signed contracts with Havana to acquire Cuban vaccines, “There is interest in Argentina” and in “countries in Asia”.
“All the vaccines that we are going to produce in the remainder of the year, all are compromised, and we have not wanted to close other agreements, because (…) we want to meet the delivery schedules”, added.
At the close of Monday, Cuba had immunized 55.8% of its 11.2 million inhabitants with its own vaccines, to which it attributes a substantial decrease in infections in recent weeks, after COVID-19 had skyrocketed since last July.
As of Monday, the island reported 923,966 cases and 7,928 deaths.
According to the criteria of
IT MAY INTEREST YOU:
Follow us on twitter: